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osting by EAbstract Thyroid eye disease (TED) is the most common cause of orbital disease in adults. The
immunologic pathogenesis of TED has been an area of active research and considerable progress
has resulted in an expansion of therapeutic options. Although surgical intervention may be
required, a majority of TED patients can be managed with medical therapies. Of medical therapies,
glucocorticoids remain the agent of choice in the control of TED activity. The objective of this
review is to discuss the paradigm and options in medical management of TED.
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Thyroid eye disease (TED) or thyroid-associated ophthalmopa-
thy (TAO) is the most common cause of orbital disease in adults
and is a signiﬁcant cause of morbidity in patients with Graves’
disease (Scott and Siatkowski, 1999; Wiersinga and Bartalena,
2002). Approximately 25–50% of patients with Graves’ hyper-
thyroidismhaveTED,which canbe sight-threatening due todys-
thyroid optic neuropathy or corneal breakdown in 3–5% of
patients (Bartalena et al., 2000; Bahn and Heufelder, 1993).
Although the disease most commonly occurs in patients with a
history of hyperthyroidism, 10% of affected patients are euthy-
roid (6%), hypothyroid (1%) or have Hshimoto’s thyroiditis
(3%) at the time of diagnosis (Bartley et al., 1996; Burch and
Wartofsky, 1993). Most patients can be managed with non-
surgical treatments alone, and those requiring surgical interven-
tion often beneﬁt from concurrent medical therapy. This review
will not address the surgical treatments ofTEDbut ratherwill fo-
cus on the medical management of TED.2. Signs and symptoms
Clinical signs and symptoms arise from soft tissue enlargement
leading to increased pressure within the bony orbit (Bahn and
Heufelder, 1993). A majority of patients have expansion of
both extraocular muscle and adipose tissue, although some pa-
tients have a predominance of one type of tissue (Forbes et al.,
1986). Eyelid retraction is the most common sign of TED
occurring in 75–91% of patients (Rose et al., 2005) (Fig. 1).
The exact mechanism of upper eyelid retraction is unclear,
although overactive sympathetic stimulation of Muller’s mus-
cle, scarring between the levator muscle and surrounding tis-
sues, and overaction of the levator muscle as it contracts
against a tight inferior rectus muscle are possible components
(Rose et al., 2005; Waller, 1982; Small, 1995). Exophthalmos
develops as orbital contents expand. CT imaging can delineate
between TED that results predominately from fat expansion
(type 1) and TED that results predominately from extraocularmuscle enlargement (type 2) (Rose et al., 2005). Patients at high
risk of compressive optic neuropathy are those with enlarged
extraocular muscles that crowded orbital apex. Moreover, such
individuals who also lack or have minimal exophthalmos are at
highest risk of compressive optic neuropathy. Strabismus is
restrictive rather than paralytic, and is due to inﬂammation,
swelling and ﬁbrosis of extraocular muscles, particularly the
inferior and medial rectus muscles. The increased exposure of
the eye from either eyelid retraction, exophthalmos and a poor
Bells’ reﬂex may lead to corneal dryness, pain, decreased blink-
ing, lagophthalmos, chemosis, photophobia, and corneal ul-
cers. Periorbital edema may reﬂect vascular compression
within the orbit and decreased lymphatic and venous drainage.
Individuals with anatomic variability in size and shape of the
orbit or variations in lymphatic or venous drainage may be at
increased risk of manifesting the signs and symptoms of TED
(Chan et al., 2009).
3. Pathogenesis
The immunologic mechanism of TED is thought to be initiated
by autoreactive T lymphocytes directed against antigens that
Figure 2 Severe exophthalmos in thyroid eye disease.
Medical management of thyroid eye disease 5are common to the thyroid and orbit. The thyrotropin receptor
and the insulin-like growth factor I receptor are the commonly
implicated shared autoantigen although conﬁrmatory research
is ongoing (Tsui et al., 2008). The autoantigen calsequestrin in
extraocular muscles and collagen XIII in orbital ﬁbroblasts are
reported to be diagnostic markers of TED and may also con-
tribute to the disease process (Gopinath et al., 2007, 2009).
Mononuclear cell inﬁltration consisting of helper/inducer
CD4+ and suppressor/cytotoxic CD8+ T lymphocytes, B
lymphocytes, plasma cells, and macrophages occurs in the
extraocular and levator muscles, adipose tissues, and lacrimal
gland of those with TED (Bahn, 2000; Chen et al., 2008).
Early in the disease, type 1 helper T cells predominate and se-
crete cytokines (interleukins, interferon-c, and tumor necrosis
factor). Later in the disease process, type 2 helper T cells pre-
dominate andpropagate productionof antibodies that stimulate
the receptors expressed on orbital ﬁbroblasts and adipocytes
(Aniszewski et al., 2000). Cytokines, auto-immunoglobulins,
and CD4+ T cells expressing the CD40 ligand directly activate
orbital ﬁbroblasts to produce glycosaminoglycans (Feldon
et al., 2005; Korducki et al., 1992). The cytokine cascade, ﬁbro-
blast proliferation, and expansion of adipose tissuewithin the ri-
gid conﬁnes of the bony orbit result in cosmetic and sight-
threatening consequences.4. Evaluation of thyroid eye disease
4.1. Disease phase
A primary objective in the evaluation of a patient with TED is
to determine the patient’s disease phase as a function of two
variables: activity and severity. Discriminating between active
and inactive disease is a crucial step in treatment decision mak-
ing. Activity can be thought of as the degree to which the body
is reacting to autoantigen. Patients with a Clinical Activity
Score (CAS) P3/7 should be considered as having active
TED (Mourits et al., 1989, 1997). Qualitatively, activity can
be considered inactive, moderately active and severely active.
Clinical Activity Score (Mourits et al., 1997):
Pain 1. Painful, oppressive feeling on or behind the
globe, during the last 4 weeks
2. Pain on attempted up, side or down gaze
during the last 4 weeks
Redness 3. Redness of the eyelid(s)
4. Diﬀuse redness of the conjunctiva, covering
at least one quadrant
Swelling 5. Swelling of the eyelid(s)
6. Chemosis
7. Swollen caruncle
8. Increase of proptosis of P2 mm during a
period of 1–3 months
Impaired
function
9. Decrease of eye movement in any
direction P5 deg during a period
of 1–3 months
10. Decrease of visual acuity of
10. Decrease of visual acuity of P1 line(s)
on the Snellen chart (using a pinhole)
during a period of 1–3 monthsSeverity on the other hand is the physical sequelae of activity,
however, those changes may remain despite control of activity;e.g. a person may have chronic diplopia and exophthalmos
although she/he has inactive disease (Fig. 2). The Consensus
Statement of the European Group on Graves’ Orbitopathy
recommends stratifying disease severity into the following cat-
egories to help guide treatment (Bartalena et al., 2008):
(1) Sight-threatening TED: patients with dysthyroid optic
neuropathy (DON), eyeball subluxation, choroidal folds
and/or corneal breakdown; these patients warrant
immediate intervention. Treatment for DON may
include steroids, surgery or both (Marcocci et al.,
2001; Macchia et al., 2001; Kauppinen-Makelin et al.,
2002; Kahaly et al., 2005).
(2) Moderate to severe TED: patients without sight-threat-
ening disease, but whose eyes have sufﬁcient impact on
quality of daily life to warrant the risk of rehabilitative
surgery (if inactive) or the risks of immunosuppression
and/or orbital radiotherapy (if active). Common symp-
toms include: lid retraction P2 mm, exophthalmos
P3 mm above normal for race and gender, moderate
to severe soft tissue involvement, and intermittent or
constant diplopia.
(3) Mild TED: patients with features that have minor
impact on quality of daily life. Watchful waiting is
appropriate for the majority of patients. Risk of immu-
nosuppression or surgery is typically not justiﬁed in this
group unless there is progression. Common symptoms
include: minor lid retraction <2 mm, exophthalmos
<3 mm above normal for race and gender, mild soft tis-
sue involvement, transient or no diplopia, and corneal
exposure responsive to lubricants (Bartalena et al.,
2000). Even minor disﬁgurement can impact the
patient’s quality of life, and intervention may be offered
to patient if individualized analysis of risks and beneﬁts
favor treatment.
4.2. Imaging
CT imaging is often adequate for those with TED. It is not
essential in all patients, but should be considered in those
with atypical presentations, e.g. strabismus affecting the lat-
eral rectus, non-axial globe proptosis, suspected optic neu-
6 D.D. Yang et al.ropathy and before orbital decompression (Rose et al.,
2005).
4.3. Serum markers
Laboratory makers provide diagnostic as well as therapeutic
assistance. Therapeutically, serum markers guide and gauge re-
sponse to treatment, and may help identify patients at risk for
disease progression. Recent research has focused on the path-
ogenic role of thyrotropin receptor autoantibodies (TRAb) or
thyroid stimulating hormone stimulating antibodies (TSAb),
in Graves’ disease. The thyroid stimulating hormone receptor
(TSHR) is over-expressed in orbital ﬁbroblasts and adipose
tissue in TED patients (Heufelder, 1995; Paschke et al., 1995;
Crisp et al., 1997; Spitzweg et al., 1997). Higher levels of
TSHR mRNA expression are found in patients with clinically
active disease when compared to patients with inactive TED
(Wakelkamp et al., 2003). Autoantibodies to thyroid antigens
are associated with TED at the onset of the disease (Tsui et al.,
2008; Gopinath et al., 2007, 2009; Stiebel-Kalish et al., 2010).
The increased level of autoantibodies and TSHR expression in
patients with TED suggests that serum markers may be useful
in conﬁrming the diagnosis.
In addition to the commonly tested serum markers, free T4,
T3, thyroglobulin, and TSH, there are several additional vari-
ables that correlate with TED. Thyroglobulin (TgAb) and thy-
roid perioxidase (TPOAb) are both auto-immunoglobulin
markers of TED. TgAb are less prevalent and less useful than
TPOAb for prediction of thyroid dysfunction (McLachlan and
Rapoport, 2004). The thyrotropin binding inhibitory immuno-
globulins (TBII) assay quantiﬁes the titer of auto-immunoglob-
ulins that inhibit the binding of TSH to puriﬁed or recombinant
TSHR, thereby measuring both thyroid stimulating antibodies
(TSI) and thyroid blocking antibodies. Alternatively, a bioassay
can be used to distinguish between stimulating- and blocking-
autoantibodies via their effect on cyclic adenosine monophos-
phate (cAMP) in a cell line transfected with the receptor (Stan
and Bahn, 2010). It is possible that yet unrecognized or unde-
tected neutral TSHR antibodies or subsets of TSHR-directed
antibodies play a role in orbital ﬁbroblast signaling.
Older studies reported limited utility of TSHR antibody
levels (Gerding et al., 2000; Feldt-Rasmussen et al., 1981; Teng
et al., 1977; Wall et al., 1979; McKenzie, 1967). These studies
have been criticized for using ﬁrst generation TBII assays or
long-acting thyroid stimulator assays (now known to be insen-
sitive) and including patients with inactive disease (Stan and
Bahn, 2010). Despite the insensitive assays, a few of these older
studies did report correlation between long-acting thyroid
stimulatory activity and severity of TED (Lipman et al.,
1967; Morris et al., 1988; Kosugi et al., 1990).
Several newer studies investigated whether auto-immuno-
globulins correlated with symptoms of TED. Two reports
found a positive correlation between the prevalence of TED
and levels of TSI but not levels of TBII (Khoo et al., 1999;
Noh et al., 2000). Later report by Goh et al. supported this
ﬁnding; TSI was a positive predictor, while TPOAb and TgAG
were both negative predictors of chronic lid retraction, lid
swelling, proptosis, and extraocular myopathy (Goh et al.,
2004). Also, Khoo et al. detail that absent autoantibodies to
TPO coupled with high TSI levels identify a group at high risk
for TED (Khoo et al., 1999). The simultaneous presence ofTBII and TSAb (odds ratio: 4.9 activity, 9.0 severity) was sig-
niﬁcantly associated with higher activity and severity of disease
than the presence of TBII without measurable TSAb (odds ra-
tio: 2.1 activity, 2.0 severity) (Eckstein et al., 2004). Gerding et
al. also found a highly signiﬁcant correlation between the CAS
and both TBII and TSI (Gerding et al., 2000). Recent report
by Dragan et al. supports the correlation between TSI values
and changes in clinical severity score (Dragan et al., 2006).
In contrast, Kung et al. reported that the development of
new or exacerbation of TED after radioactive iodine therapy
did not correlate with TRAb titers (Kung et al., 1994).
Subsequent investigations focused on using TRAb levels to
predict response to therapy. Eckstein et al. demonstrated that
TBII titers remained detectable in 14 of 15 (93%) patients who
were unresponsive to anti-inﬂammatory therapy compared to
22 of 52 (42%) patients who responded to therapy (Eckstein
et al., 2004). Study by Kahaly et al. also demonstrated a de-
crease in TRAb that correlated with an improvement in CAS
score after intravenous glucocorticoid therapy (Kahaly et al.,
2005). Eckstein et al. followed TBII levels every 3 months for
12–24 months in 159 TED patients and were able to predict
the TED progression (whether mild or severe) in 50% of pa-
tients (Eckstein et al., 2006). Further studies are needed to clar-
ify the role of auto-immunoglobulin levels in the management
of TED but preliminary studies suggest that they are useful in
diagnosis and may be a predictor of progression risk.5. Systemic thyroid disease
5.1. Anti-thyroid meds
Patients with TED or suspected TED should be referred to an
internist or an endocrinologist for evaluation and management
of systemic thyroid disease. Anti-thyroid drug (ATD) therapy
may help reduce orbit-directed autoimmune reactions but does
not alter the course of existing TED (Marcocci et al., 1992).
However, medical management of thyroid function is essential
as patients with uncontrolled hyper-and hypothyroidism are
more likely to have severe TED than euthyroid patients
(Prummel et al., 1990). No particular drug or drug regimen
has demonstrated any advantages in the management of
TED (Bartalena et al., 2008).
Methimazole, carbimazole, and propylthiouracil are the
main drug treatments blocking thyroid hormone synthesis. They
are frequently used in an attempt to achieve remission or as pre-
parative therapy before radioactive iodine or thyroid surgery.
After active concentration by the thyroid, the drugs inhibit thy-
roid peroxidase mediated iodination of tyrosine residues in thy-
roglobulin. Propylthiouracil had the additional beneﬁt of
inhibiting the peripheral conversion of thyroxine (T4) into triio-
dothyronine (T3). Decrease in thyrotropin receptor antibodies,
IL-2 and IL-6 receptors, HLA class II expression, and intracel-
lular adhesion molecule are seen with treatment; it is unclear
whether these are direct effects of the drugs or are the result of
normalization of thyroid function (Cooper, 2005; Laurberg,
2006). Serious side effects occur in less than 0.3% patients and
include agranulocytosis, hepatotoxicity, and vasculitis (Cooper,
2005; Harper et al., 2004). Overall, the recurrence rate of hyper-
thyroidisms is 50–60%, with most cases occurring within 3–
6 months of drug cessation.
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imen (where a higher dose of anti-thyroid drug is given with
a replacement dose of thyroid hormone) or by the titration
regimen (where the anti-thyroid drug is reduced by titrating
treatment against thyroid hormone concentrations). A meta-
analysis by Abraham et al. summarized 26 randomized trials
evaluating different ATD regimens (Abraham et al., 2005).
Twelve trials examined the effect of block-replace versus
titration regimens. The relapse rate of hyperthyroidism was
similar in both groups; 51% in the block-replace group
and 54% in the titration block-group (OR 0.86, 95% conﬁ-
dence interval (CI) 0.68–1.08). Adverse effects and withdraw-
ing due to side effects (16% versus 9%) were signiﬁcantly
higher in the block-replace group. Trials that studied the ef-
fect of duration of therapy on relapse rates showed that
when using the titration regimen for 12 months was superior
to 6 months, but no beneﬁt was seen by extending the treat-
ment beyond 18 months (Allannic et al., 1990; Maugendre
et al., 1999; Weetman et al., 1994; Garcia-Mayor et al.,
1992). Authors concluded that 12–18 months of the titration
regimen had fewer side effects but had the same efﬁcacy
than the block-replace regimen.
5.2. Radioactive iodine
Radioactive iodine (RAI), or 131I, can be given orally and is
rapidly concentrated by thyroid follicular cells. The ionizing
effect of b particles induces an inﬂammatory response and
subsequent necrosis of follicular cells. The typical amount
of RAI given is 5–15 mCi to yield an absorbed radiation
dose of 50–100 Gy. Following administration, thyroid func-
tion declines over weeks to months and symptoms can be
managed with B-adrenergic antagonists or ATD in the inter-
im. Due to its radioprotective effects, ATD are usually dis-
continued 4 days prior to administration of 131I (Bonnema
et al., 2002). The period of interruption is intended to de-
crease the risk of relapse into hyperthyroidism and cardio-
vascular complications.
Radioiodine has been associated with disease progression in
some patients with TED or newly diagnosed eye disease (15%).
This risk is commonly mitigated with prophylactic steroid cover
(0.3–0.5 mg of oral prednisone/kg body weight per day for 1–
3 days after RAI) with taper until withdrawal at 3 months
(Bartalena et al., 1998). Review of ﬁve randomized control trials
examining the use of glucocorticoid prophylaxis with RAI
showed that prednisolone was highly effective in preventing
the progression of TED in patients with pre-existing TED
(RR 0.03; 95% CI 0.00–0.24) (Acharya et al., 2008). Patients
with inactive TED can receive radioiodine without steroid pro-
phylaxis, as long as no other risk factors (i.e. smoking, high thy-
rotropin-receptor antibody >7.5 IU/L) are present and
hypothyroidism is avoided (Bartalena et al., 2008; Eckstein
et al., 2006; Perros et al., 2005). Of those with exacerbation of
TED, approximately 5% had worsening that persisted at one
year and required additional treatment (Bartalena et al., 1989).
Long term hypothyroidism is common with an estimated
incidence of 2–3% annually and is managed with thyroid hor-
mone supplementation. The incidence of early hypothyroidism
is associated with increased 131I dose, autoantibodies to
TPOAb, hypoechogenicity on ultrasound, and enlarged gland
(Ahmad et al., 2002).5.3. Thyroid surgery
The goal of thyroidectomy, regardless of the type total, near
total, or subtotal surgery, is to correct thyroid function while
minimizing recurrence and complication rates. Hypoparathy-
roidism and permanent damage to the recurrent laryngeal
nerve occur in at least 1–2% and rates up to 5–10% have been
reported (Sosa et al., 1998). Transient hypocalcemia, wound
infections, keloids, and postoperative bleeding are common
complications.
Thyroidectomy has not demonstrated any advantage in the
outcome of TED but is indicated for long-term control of thy-
roid function (Bartalena et al., 2008). Subtotal thyroidectomy
carries a smaller complication rate than total or near total re-
moval but 5–15% of patients have recurrence of hyperthyroid-
ism (Hoffmann, 2009). Due to the high recurrence rate, total
or near total thyroidectomy is typically performed. This risk
of recurrence is directly related to the size of thyroid remnant,
initial TSHRAb level, and the presence of TED (Werga-
Kjellman et al., 2001). Total ablation may not be achieved
by thyroidectomy alone. Compared to thyroidectomy alone,
thyroidectomy followed by RAI is associated with better out-
comes and this combination is routinely performed in order to
achieve total ablation (Menconi et al., 2007).
In routine and non-urgent cases, the goal is to optimize the
patient’s thyroid function before surgery. Preoperative inor-
ganic iodine (saturated solution of potassium iodide, or SSKI)
is given for 10 days to decrease blood ﬂow to the thyroid. If the
patient cannot tolerate anti-thyroid medications or requires ur-
gent surgery, betamethasone, B-adrenergic antagonist, and
SSKI can be given for 5 days before surgery (Baeza et al.,
1991; Henley et al., 2006).6. Management of thyroid eye disease
6.1. Smoking cessation
The strongest modiﬁable risk factor for disease progression
is cigarette smoking (odds ratio among smokers versus non-
smokers, 7.7 (Wiersinga and Bartalena, 2002)). A systematic
review by Thornton et al. of 15 studies found dose-depen-
dent relationship between smoking and disease severity and
concluded that smokers have poorer treatment outcome
(Thornton et al., 2007). In a trial of patients with newly
diagnosed TED treated with either radioactive iodine or
anti-thyroid drugs, smokers had the highest overall risk for
the development or progression of TED irrespective of the
treatment modality (Traisk et al., 2009). Smokers who un-
dergo radioactive iodine therapy have the highest incidence
of unfavorable TED outcome, and this risk is proportional
to the number of cigarettes smoked per day (Stan and Bahn,
2010).
The mechanism underlying the link between cigarette
smoking and TED is unclear. In vitro studies have suggested
oxygen reactive species may lead to proliferation of orbital
ﬁbroblasts (Bartalena et al., 2003). Cigarette smoke extract
synergized with interleukins in promoting adipogenesis in orbi-
tal tissue (Cawood et al., 2007). Smoking cessation is a crucial
aspect of medical management to halt disease progression and
to promote favorable treatment outcomes.
Figure 3A Right upper eyelid retraction before treatment with
botulinum toxin injection.
Figure 3B One-week after treatment of botulinum toxin injec-
tion to right upper eyelid. Note: signiﬁcant improvement in right
upper eyelid position.
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Many patients with TED can be managed with minimal inter-
vention. Lubrication with artiﬁcial tears, gels and ointments
often provide symptomatic relief. Patients may also beneﬁt
from using cool compresses, sleeping with an elevated head
of bed and taping of the eyelids. If patients are symptomatic
from exposure keratopathy from eyelid retraction botulinum
toxin can be successfully utilized (Uddin and Davies, 2002;
Shih et al., 2004) (Figs. 3A and 3B).
6.3. Intravenous corticosteroids
Glucocorticoids are used as a method of medical decompres-
sion due to their anti-inﬂammatory and immunosuppressive
properties. Intravenous glucocorticoid (IVGC) is a short-term
and urgent treatment used to decelerate disease activity in pa-
tients with sight-threatening disease, although it may be con-
sidered in patients with active moderate to severe TED. A
commonly used regimen consists of 12 weekly infusions of
methylprednisolone (500 mg weekly for 6 weeks, then 250 mg
weekly for 6 weeks) with a cumulative dose of 4.5 g (Kahaly
et al., 2005). Patients with sight-threatening dysthyroid optic
neuropathy require immediate high-dose IVGC, usually 1 g
of methylprednisolone for three consecutive days with subse-
quent response based dose titration. If there is no improvementafter 1–2 weeks, then prompt surgical orbital decompression
may be considered (Bartalena et al., 2008).
The approximate percentage of positive response to IVGC
is over 70% (ranges from 33% to 100%), which is higher than
the response rate to oral or local corticosteroids (Bartalena
et al., 2000). Two randomized trials have shown that IV ther-
apy is more effective than oral therapy (88% versus 63% by
Marcocci et al. (2001); 77% versus 51% by Kahaly et al.
(2005)). In a small randomized trial, immediate decompression
surgery as the ﬁrst choice therapy does not appear to be asso-
ciated with better outcomes compared to IVGCs as the ﬁrst
therapy (Wakelkamp et al., 2005).
Acute and severe organ damage has been reported in
sporadic cases. Marino et al. reported seven cases of acute
liver damage in patients without prior overt liver disease,
three of whom died (Marino et al., 2004). The patients
had been treated with either 131I or thyroidectomy and were
euthyroid on levothyroxine when they underwent IV methyl-
prednisolone acetate (IVMP). A prospective observational
study of 13 patients with moderate to severe TED by Le
Moli et al. demonstrated that IVMP causes dose-dependent
liver damage but appears safe if cumulative dose remains
under 8 g (Le Moli et al., 2007). One case report of new on-
set heart failure was attributed to IVMP pulse therapy
superimposed on thyrotoxicosis-related hemodynamic insta-
bility (Gursoy et al., 2006). Due to these serious risks, pa-
tients should be screened for co-morbid medical conditions
and monitored closely during the course of therapy.6.4. Oral corticosteroids
Oral glucocorticoids are frequently used in the treatment of
TED although they are associated with systemic side ef-
fects. The long term consequences are more pronounced
since oral therapy is typically given for a longer period
of time than intravenous or local glucocorticoids. Oral glu-
cocorticoids can be given at high doses, such as prednisone
80–100 mg/day (or about 1 mg/kg body weight) followed by
10 mg/week taper (Kahaly et al., 2005; Brauer and Scholz,
2004). Need to mention typical duration of therapy men-
tioned in studies.
Cushionoid features, increased risk of diabetes, infections,
osteoporosis, hypertension, hirsutism, and cataract formation
limit their long term use. Monitoring of glycemic and blood
pressure is especially crucial in patients with pre-existing diabe-
tes or hypertension. During treatment with high dose GC, thi-
azide and loop diuretics should be used cautiously to avoid
hypokalemia. Prolonged oral GC therapy >5 mg average dai-
ly dose of prednisone for >3 months requires bisphosphonates
or other antiresorptive drugs (Tamura et al., 2004). Therapy
should be tapered slowly upon cessation to avoid ﬂares and
cortisol deﬁciency.
Approximately 60% of patients have favorable effects of
high dose oral GC (reports range from 40% to 100%)
(Bartalena et al., 2000). Open trials or randomized studies
comparing oral GC with other treatments have shown a favor-
able response in about 33–63% of patients with soft tissue
changes, recent onset eye muscle involvement, and DON
(Bartalena et al., 1983; Prummel et al., 1993; Kung et al.,
1996; Kahaly et al., 1996).
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Retrobulbar or subconjunctival glucocorticoid injections are
less effective than oral or IVGCs but can be considered when
oral or IVGCs are contraindicated. Risks of this invasive pro-
cedure include exacerbation of proptosis, infection, globe
perforation, corneoscleral or conjunctival melting, occlusion
from embolization, pressure induced optic nerve compression,
depigmentation, granuloma reaction to methyl cellulose, fat
atrophy, and elevated IOP (Nozik, 1976).
Several studies have reported varied degrees of successwith lo-
cal corticosteroid deposition. Marcocci et al. compared 30 pa-
tients treated with systemic GC tapered over 6 months versus 44
patients treated with retrobulbar injections (14 methylpredniso-
lone bilateral injections at 20–30 day intervals). All patients were
also treated with irradiation (total dose 2000 rads). The treatment
group receiving localGChad 25% favorable result rate, while the
group receiving systemic CS had 60% favorable result rate (Mar-
cocci et al., 1987). The authors concluded that although response
rate is lower with local administration, the adverse effects are
milder than with systemic GC administration. Poonyathalang et
al. also studied the efﬁcacy of retrobulbar triamcinolone injec-
tions onceweekly for 4 weeks in27eyesof 19previouslyuntreated
patients. At 3 months, a reduction of P1 mm of proptosis was
seen in 56% of the eyes, no change in 37%, and a worsening in
7%. Results were stable at 6 months follow-up. EOM function
was improved in 41% of patients at 3 months. Eight eyes were
noted to have increase in IOP that responded to topical glaucoma
medications (Poonyathalang et al., 2005).
There are two studies evaluating peribulbar triamcinolone
injections. In a randomized control study, Ebner et al. divided
41 patients with early TED into either the treatment group
receiving 4 weekly peribulbar injections (triamcinolone 20 mg
injected to the inferolateral orbital quadrant) or the control
group without injections. The study found an increase in the
area of binocular vision without diplopia in the treatment
group. The size of extraocular muscles (initial compared to ﬁ-
nal size) was signiﬁcantly decreased at 24 weeks in the treat-
ment group. No adverse ocular or systemic side effects were
reported (Ebner et al., 2004). In a prospective case study by
Bordaberry et al., 11 patients with moderate disease and 10 pa-
tients with optic neuropathy underwent peribulbar triamcino-
lone injections (20 mg injected at inferolateral or superomedial
quadrants at 2 week intervals for four total doses). Mean dif-
ference of 4.57 ± 1.56 points on CAS evaluation was found
between initial and post-treatment. Of the 10 patients with
ON, 66% improved with peribulbar triamcinolone exclusively.
Two patients had transitory increased IOP which was con-
trolled with topic medication (Bordaberry et al., 2009).
The data from these small studies suggest that local cortico-
steroids may be considered as an adjunctive therapy or used in
patients who cannot tolerate other forms of GC. Although local
therapy has decreased efﬁcacy compared to oral or IV cortico-
steroids, the lower rate of systemic effectsmay be an appropriate
alternative for patients with co-morbid medical conditions.
6.6. Orbital irradiation
Orbital irradiation (OR) may be considered in patients with ac-
tive disease with severe TED. Furthermore, in a review of 624
patients, Bartalena et al. found that recent optic neuropathyand soft tissue changes responded better than proptosis or
extraocular muscle disease (Bartalena et al., 2002). OR has
anti-inﬂammatory effects and alters the helper/suppressor T
lymphocyte ratio (Bartalena et al., 1998). The most commonly
delivered cumulative dose is 20 grays per eye, fractionated in
10 daily doses. OR with lower doses (10 Gy) may be effective
and better tolerated than the traditional higher dose (Kahaly
et al., 2000). Risk of exacerbation of inﬂammatory symptoms
is decreased by giving glucocorticoids concomitantly (Bartalena
et al., 1983).
Complications from OR are rarely reported, but are con-
cerning. The risk of cataract formation caused by irradiation
of the lens is minimized by fractionating the dose. Radiation
retinopathy is a rarely reported complication. Patients with se-
vere hypertension or diabetic retinopathy should not be treated
with radiation as retinal microvascular abnormalities have
been detected in a minority of these groups (Robertson
et al., 2003; Viebahn et al., 1991). Evidence is unclear whether
diabetic patients without retinopathy are at increased risk of
developing retinal changes, thus diabetes without retinopathy
should be regarded as a relative contraindication (Marcocci
et al., 2003; Wakelkamp et al., 2004). There is a theoretical cal-
culated risk of 0.3–1.2% for occurrence of secondary tumors
but no cases of radiation-induced tumors have been reported
in Graves’ patients (Broerse et al., 1999). Orbital radiation
should be avoided in patients younger than 35 due to the po-
tential carcinogenic effects (Bartalena et al., 2008).
Approximately 60% of patients have favorable response to
OR (range 20–92%) (Bartalena et al., 2000). Combined treat-
ment of OR with oral glucocorticoids is more effective than
either treatment alone (Bartalena et al., 2000; Stiebel-Kalish
et al., 2009). In a randomized trial comparing OR with oral
glucocorticoids, both were found to be equally effective as ini-
tial treatment (Prummel et al., 1993). There is a lack of ran-
domized studies comparing the combination of IV
glucocorticoids with OR versus IV glucocorticoids alone.
The efﬁcacy of irradiation is still controversial due to three
trials that evaluated sham irradiation (Prummel et al., 2004;
Mourits et al., 2000; Gorman et al., 2001). Retrobulbar radio-
therapy therapy (total of 20 Gy in 10 divided fractions) was
administered in the treatment groups of all studies and fol-
low-up period ranged from 24 weeks to 1 year. The response
rate of diplopia was better in the radiotherapy group as com-
pared to the sham-irradiated group. No improvement was seen
in CAS, exophthalmos and lid aperture outcomes were ob-
served in the irradiated groups. The conﬂicting reports on
the efﬁcacy of OR merits further study.
6.7. Novel treatments
Advances in the understanding of the pathogenesis and immu-
nologic basis of TED have lead to the advent of new potential
treatment modalities. They include monoclonal antibodies and
immunomodulators, such as rituximab, TNFa inhibitors, and
somatostatin analogs, are the emerging research modalities.
We will give a brief overview of the new research treatments.
6.8. Rituximab
Rituximab (RTX) is a monoclonal antibody directed against
the CD20 antigen expressed on the surface of B lymphocytes.
Potentially, decreasing B cell function will result in decreased
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including the TSH-receptor and IGF-1 receptor antibodies.
Rituximab has been shown to deplete intrathyroidal B-cells
in Graves’ disease and thus may have a therapeutic role (El
Fassi et al., 2007). Common adverse side effects include serum
sickness, infusion reaction, and increased infections.
Several studies summarized below have shown varying de-
grees of beneﬁt. Salvi et al. compared RTX with intravenous
glucocorticoid in a nonrandomized pilot study in patients with
mild to moderate disease (Salvi et al., 2007). Nine patients
treated with RTX (1000 mg IV · 2 with 2 week interval) and
20 patients were treated with IVGC (500 mg IV for 16 weeks).
Thyroid function was not affected but exophthalmos and clin-
ical signs improved in patients treated with RTX. Patients
treated with RTX had more CAS improvement than patients
treated with intravenous glucocorticoids (P< .05).
In a controlled nonrandomized study byEl Fassi et al., 10 pa-
tients receivedmethimazole before RTX therapy (375 mg/m2 IV
on day 1, 8, 15, and 22) and 10 patients received methimazole
only (El Fassi et al., 2007). Both groups were withdrawn from
methimazole and followed for signs of relapse and autoantibody
levels. Four of the RTX treated patients remained in remission
(median follow up of 705 days), whereas all of the patients with-
out RTX treatment had relapsed by day 393. Patients who re-
mained in remission had low initial TSH receptor antibody
levels. Authors concluded that RTX treatment may induce sus-
tained remission in patientswith lowTRAb levels.Aprospective
phase II study by Heemstra et al. included 13 patients with
relapsing Graves’ disease who received two doses of RTX
(1000 mg IV with a 2 week interval) (Heemstra et al., 2008).
The proportion of lymphocytes in peripheral blood decreased
from 5.8% before treatment to 1.4% at 26 weeks suggestive of
a decreased immune response to RTX (P= 0.007). Four pa-
tients with high initial FT4 did not respond to treatment, while
all remaining patients had a decrease in FT4 levels at 26 weeks
and an increase in TSH. At follow-up (14–27 months), nine of
the patients were still euthyroid.
Most recently, Khanna et al. reported a case series of six
patients with severe progressive TED unresponsive to gluco-
corticoids (Khanna et al., 2010). CAS improved from
5.5 ± 0.8 to 1.3 ± 0.5 at 2 months after treatment with RTX
(P< 0.03). Vision was improved in all four patients with
DON and exophthalmos remained stable in all patients. Due
to high cost and potential toxicity, current evidence does not
support RTX use in uncomplicated disease.6.9. TNFa inhibitors
The cytokine tumor necrosis alpha (TNFa) is found to be
over-expressed in the orbital connective tissue of those with
TED. Studies using anti-TNFa agents, such as etanercept,
adalimumab, and inﬂiximab, have been limited. Durrani et
al. treated one patient with sight-threatening disease with inf-
liximab (Durrani et al., 2005). Paridaens et al. conducted a
prospective, noncontrolled study with 10 patients with active
mild to moderate disease who were treated with subcutaneous
entanercept 25 mg twice weekly for 12 weeks (Paridaens et al.,
2005). The CAS and ophthalmopathy index scores decreased
by 60% and 24%, respectively. There was an improvement
in soft tissue changes but inﬂammatory signs recurred in three
subjects 2–6 weeks after the end of treatment. No change inmean exophthalmometry was observed. No adverse events or
side effects have been reported in the treatment of TED pa-
tients. Bongartz et al. analyzed nine studies that administered
inﬂiximab and adalimumab to rheumatoid arthritis patients
and found an increased risk of serious infections and malig-
nancies (Bongartz et al., 2006). TNFa inhibitors may be a
potentially useful tool but more studies are necessary to eval-
uate its safety and efﬁcacy.
6.10. Somatostatin analogs
There are ﬁve somatostatin receptor subtypes, and all except
subtype 4 are expressed in orbital lymphocytes and ﬁbroblasts
of TED patients (Pasquali et al., 2000). These receptors are
thought to contribute to adipocyte proliferation. Although
initial uncontrolled studies showed positive results, four ran-
domized, placebo-controlled clinical trials with long-acting
octreotide or lanreotide have demonstrated marginal efﬁcacy
in treatment of TED (Dickinson et al., 2004; Wemeau et al.,
2005; Chang and Liao, 2006; Stan et al., 2006). Pasireotide
(SOM230) is a new somatostatin analog undergoing develop-
ment that targets a wider range of somatostatin receptors. Cell
cultures show that SOM230 produced signiﬁcantly greater
inhibition of orbital preadipocyte proliferation than octreotide
and may become a promising new treatment (Cozma et al.,
2007).
6.11. Other immunomodulators
There have been several reports of using novel immunomodu-
lators without consistent success. Two small studies have
shown that the combination of oral GCs and cyclosporine is
superior to either treatment alone (Kahaly et al., 1986; Prum-
mel et al., 1989). Azathioprine (Perros et al., 1990), ciamexone
(Kahaly et al., 1990), and IV immunoglobulins (infusion of
IgG antibodies isolated from human plasma donors) (Kahaly
et al., 1996; Antonelli et al., 1992) have marginal or unproven
value. Other agents approved for rheumatoid arthritis, such as
abatacept (costimulatory blocker of T-cell activation), and
anakinra (interleukin-1 receptor antagonist) have yet to be
tested in patients with TED (Griepentrog and Garrity, 2009).7. Conclusion
Thyroid eye disease is a common cause of orbital disease in
adults. The pathogenesis is an active area of research and
many immunologic aspects of the disease have been elucidated.
Research of serum markers may assist in the diagnosis, prog-
nosis and response to therapy through their ability to improve
the classiﬁcation of TED patients. Characteristic enlargement
of the extraocular muscles and proliferation of adipocytes re-
sult in the clinical ﬁndings, such as eyelid retraction, exoph-
thalmos, and strabismus of TED. All patients require
management of their systemic thyroid disease. Most cases of
TED can be managed conservatively. Symptomatic treatment
with lubrication often sufﬁces for those with mild TED.
Individuals with moderate to severe TED may require an esca-
lation of therapy including steroids, radiation or immunomod-
ulation. Intravenous glucocorticoids have the best response
rate and the lowest incidence of side effects and thus play a sig-
Medical management of thyroid eye disease 11niﬁcant role in the management of moderate to severe as well
as sight-threatening TED. Surgical management is required
when medical management fails. An emerging understanding
of the immunologic pathogenesis will likely evolve the manage-
ment of TED over the next decade.Financial support
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